ImmuneOnco was awarded Star Light List-2019 China's Top 50 Biopharmaceutical Enterprises with the Most Innovative Ability
On August 4, 2019, ImmuneOnco won the award of Star Light List - the top 50 innovative enterprises of China's biomedical enterprises in 2019. The selection was made by enterprises in the field of bio-innovative drugs from the front line of the country, including a large part of companies which were the domestic pharmaceutical industries and listed in stock market. They were screened by experts and institutions in the relevant fields of the industry. With its unique immune regulatory target CD47 antibody product technology and the world's leading antibody-receptor recombinant protein (mAb-Trap) technology, strong R&D and innovation capabilities, ImmuneOnco has emerged from hundreds of pharmaceutical enterprises and successfully selected "China's top 50 Biopharmaceutical Enterprises with the most innovative ability".
Dr. Tian Wenzhi, founder and CEO of ImmuneOnco, thanks industry experts and relevant organizations for their recognition of the company's R&D strength and industry status. Dr. Tian said that ImmuneOnco would continue to work hard to accelerate the development of immunotherapy products to feed back society.
On August 3, 2019, the two-day Global CDMO Development Summit Forum on Biopharmaceuticals and the Star Light List -2019 Award Ceremony for the Top 50 Most Innovative Enterprises of Biopharmaceuticals in China, hosted by Emedclub, opened at Suzhou Sheraton Fupeng Hotel, Suzhou Industrial Park. More than 400 leading CDMO companies and related biopharmaceutical companies were invited to discuss the technology sharing and development of innovative drug CDMO.